Multiplying therapies and reducing toxicity in metastatic melanoma

References

• Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371(20):1877–88; PMID:25265492; http://dx.doi.org/10.1056/NEJMoa1406037
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371(20):1867–76; PMID:25265494; http://dx.doi.org/10.1056/NEJMoa1408868
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372(1):30–9; PMID: 25399551; http://dx.doi.org/10.1056/NEJMoa1412690
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372(4):320–30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371(23):2189–99; PMID:25409260; http://dx.doi.org/10.1056/NEJMoa1406498
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1):5–29; PMID: 25559415; http://dx.doi.org/10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Morrison DK, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol 1997; 9(2):174–9; PMID:9069260; http://dx.doi.org/10.1016/S0955-0674(97)80060-9
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Lorusso PM, Flaherty KT. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res 2013; 19(19):5283–91; PMID:24089441; http://dx.doi.org/10.1158/1078-0432.CCR-13-2151
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. The role of BRAF V600 mutation in melanoma. J Transl Med 2012; 10:85; PMID:22554099; http://dx.doi.org/10.1186/1479-5876-10-85
   PubMed Web of Science ®Google Scholar
• Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg 1991; 214(5):627–36; PMID:1953117; http://dx.doi.org/10.1097/00000658-199111000-00014
   PubMed Web of Science ®Google Scholar
• Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29(10):1239–46; PMID:21343559; http://dx.doi.org/10.1200/JCO.2010.32.4327
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95(5):581–6; PMID:16880785; http://dx.doi.org/10.1038/sj.bjc.6603291
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26):2507–16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380(9839):358–65; PMID:22735384; http://dx.doi.org/10.1016/S0140-6736(12)60868-X
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367(2):107–14; PMID:22663011; http://dx.doi.org/10.1056/NEJMoa1203421
   PubMed Web of Science ®Google Scholar
• Savage JA, Maize JC. Keratoacanthoma clinical behavior: a systematic review. Am J Dermatopathol 2014; 36(5):422–9; PMID:24366198; http://dx.doi.org/10.1097/DAD.0000000000000031
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366(8):707–14; PMID:22356324; http://dx.doi.org/10.1056/NEJMoa1112302
   PubMed Web of Science ®Google Scholar
• Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014; 15(4):436–44; PMID:24582505; http://dx.doi.org/10.1016/S1470-2045(14)70051-8
   PubMed Web of Science ®Google Scholar
• Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30(3):316–21; PMID:22067401; http://dx.doi.org/10.1200/JCO.2011.36.7680
   PubMed Web of Science ®Google Scholar
• Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366(3):207–15; PMID:22256804; http://dx.doi.org/10.1056/NEJMoa1105358
   PubMed Web of Science ®Google Scholar
• Lacouture ME, O'Reilly K, Rosen N, Solit DB. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J Clin Oncol 2012; 30(3):329–30; PMID:22067405; http://dx.doi.org/10.1200/JCO.2011.38.2895
   PubMed Web of Science ®Google Scholar
• Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 2014;20(7):1965–77; PMID:24463458; http://dx.doi.org/10.1158/1078-0432.CCR-13-3122
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014; 4(1):94–109; PMID:24265153; http://dx.doi.org/10.1158/2159-8290.CD-13-0617
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711–23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19(19):5300–9; PMID:24089443; http://dx.doi.org/10.1158/1078-0432.CCR-13-0143
   PubMed Web of Science ®Google Scholar
• Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 1994; 23(3):704–6; PMID:7851902; http://dx.doi.org/10.1006/geno.1994.1562
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2(3):261–8; PMID:11224527; http://dx.doi.org/10.1038/85330
   PubMed Web of Science ®Google Scholar
• Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56(5):739–45; PMID:17195077; http://dx.doi.org/10.1007/s00262-006-0272-1
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677–704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384(9948):1109–17; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369(2):122–33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
   PubMed Web of Science ®Google Scholar
• Sznol M, Kluger H, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Atkins MB, Kirkwood JM, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 2014; 32:5s, (suppl; abstr LBA9003ˆ)
   Google Scholar
• Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010;23(6):820–7; PMID:20973932; http://dx.doi.org/10.1111/j.1755-148X.2010.00763.x
   PubMed Web of Science ®Google Scholar